Adopting the New Therapeutic “Lineup” to Manage ASCVD - East

Adopting the New Therapeutic “Lineup” to Manage ASCVD - East

CME/CE Broadcast Replay

Adopting the New Therapeutic “Lineup” to Manage ASCVD - East

Join expert faculty to ensure you’re appropriately managing the care of your patients with ASCVD.

Available credits: 3.50

Time to complete: 3 hours


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Managing patients with established CVD presents challenges in our practice every day. These patients may have had a prior stroke or MI and are at a very high risk of future life-threatening CV events. Join our expert faculty to hear the latest data on new and emerging statin adjuncts presented in a highly relevant and clinically applicable format. Barriers to the optimal management of ASCVD risk in many patient types (ethnicity/race/sex) will be addressed, and solutions to effectively manage such challenges in your everyday clinical practice will be provided. 

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.


    Michael Miller, MD, FACC, FAHA
    Chief of Medicine
    Corporal Michael J. Crescenz VAMC;
    Professor and Vice Chair of Medicine
    University of Pennsylvania School of Medicine
    Philadelphia, PA

    Consulting Fees: Amarin, Pfizer, 89Bio


    Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
    Clinical Pharmacist Specialist, Primary Care
    Grady Health System
    Atlanta, GA

    No relationship reported

    Aruna Pradhan, MD, MPH
    Assistant Professor of Medicine
    Harvard Medical School;
    Associate Physician
    Scientific Director, Preventive Medicine Cohorts Biorepository
    Division of Preventive Medicine
    Brigham and Women's Hospital
    Boston, MA

    Consulting Fees: Novo Nordisk
    Contracted Research:Kowa Research Institute

    James Underberg, MD, MS, FACP, FNLA
    Clinical Lipidology
    Clinical Assistant Professor of Medicine
    NYU School of Medicine
    NYU Center for Prevention of Cardiovascular Disease;
    Director, Bellevue Hospital Lipid Clinic;
    Past President, National Lipid Association
    New York, NY

    Consulting Fees:  Amgen, Esperion, Novartis
    Speakers Bureau: Alexion, Amarin, Amgen, Amyrt Pharma, Esperion
    Contracted Research: Amyrt Pharma

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Cindy Davidson has nothing to disclose. 
    • Kate Nagele has nothing to disclose.
    • Mario Trucillo, PhD, MS has nothing to disclose.
    • Kathy Wickman has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Understand the key findings of large-scale omega-3 fatty acid clinical trials and how this information relates to reducing ASCVD events in clinical practice
    • Apply recent clinical trial evidence of EPA on a case-by-case basis for patients with established CVD who are on statins and at risk of further CV events
    • Identify barriers to the implementation of effective, long-term management of ASCVD
  • Target Audience

    This activity is designed to meet the educational needs of primary care physicians and community pharmacists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) designates this activity for 3.5 Nursing contact hours. Nurses should only claim credit commensurate with the extent of their participation in the activity.

    This curriculum has been approved for 3.5 contact hours .35 CEUs by Global Learning Collaborative (GLC).  GLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Universal Activity Number for this program is JA0006235-0000-22-004-H01-P.  This learning activity is enduring based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free